Marketing authorisation based on data from 53 patients aged 11 to 18 years from one placebo-controlled trial lasting only 6 months, with no evidence of efficacy in preventing the clinical complications of diabetes, whereas this drug carries a risk of serious adverse effects. For patients in this age range, use of dapagliflozin to prevent diabetic complications is too great a gamble.
展开▼
